Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases.
Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):950-958 Authors: Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, Feng M, Cuneo KC, Lawrence TS, Owen D Abstract PURPOSE: Stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) are widely used therapies for the treatment of intrahepatic metastases; however, direct comparisons are lacking. We sought to compare outcomes for these 2 modalities. METHODS AND MATERIALS: From 2000 to 2015, 161 patients with 282 pathologically diagnosed unresectable liver metastases were treated with RFA (n = 112) or SBRT (n = 170) at a single institution. The primary outcome was freedom from local progression (FFLP). The effect of treatment and covariates on FFLP was modeled using a mixed-effects Cox model with application of inverse probability treatment weighting to adjust for potential imbalances in treatment modality. RESULTS: The median follow-up period was 24.6 months. Patients receiving SBRT had larger tumors than those treated with RFA (median, 2.7 cm vs 1.8 cm; P
ConclusionFor planners A and B, the usage of PlanIQ did not show a great improvement in the sparing of organs-at-risk whereas for planner C it made a major difference. In any case, PlanIQ contributed to a lower plan quality output variability among the different planners.
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): K.H. Shim, H.J Yoo, S.G Park, J.E Gwon, S.H Choo, J.B Choi, H.S Ahn, S.J Kim, S.I Kim
This focused issue of PET Clinics covers 2 important and hot topics in oncology: the use of PET imaging in assessing the efficacy of immunotherapy and the use of PET imaging in radiation oncology clinical practice.
This article summarizes advancements in using FDG-PET for patients with locally advanced NSCLC treated with definitive radiation therapy (RT). This article discusses prognostication of outcome based on pretreatment or midtreatment PET metrics, using textural image features to predict treatment outcomes, and using PET to define RT target volumes and inform RT dose modifications. The role of PET is evolving and is moving toward using quantitative image information, with the overarching goal of individualizing therapy to improve outcomes for patients with NSCLC.
The effectiveness of cancer treatment must be assessed early in the course of the therapy so that regimens can be tailored in an individualized manner. Whole-body metabolic burden, metabolic tumor volume and total lesion glycolysis are the newer quantitative PET metrics that reflect the overall disease burden and take into account the stage of the disease, the heterogeneous intra-tumoral metabolism and uptake of PET tracer. Immunotherapy response evaluation in solid tumors is challenging, and combined use of anatomical and molecular imaging could evolve as the optimal way for assessing treatment response to immunotherapy. ...
This article focuses on pulmonary and cardiovascular complications of radiation therapy and discusses how PET-based novel quantitative techniques can be used to detect these events earlier than current imaging modalities or clinical presentation allow.
ConclusionsRepeat quadrantectomy + RT represents an effective salvage approach and achieved local control comparable to that of salvage mastectomy.
ConclusionSBRT ( ±TACE) in highly pretreated HCC is effective and associated with excellent LC and low toxicity. SBRT may be used as definitive or bridging treatment prior to OLT. Patients with multifocal lesions have significantly decreased 1‑ and 2‑year FFHF and OS.
ConclusionConcurrent radiation therapy and sunitinib leads to diverging results of prognostic gene array testing in a relevant proportion of sarcoma patients. These changes may reflect tumor heterogeneity, local treatment effects, or prognostic changes of the disease. Caution is advised in the selection of samples and interpretation of test results.